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Abstract: Pathogenic agents can lead to severe clinical outcomes such as food poisoning, 
infection of open wounds, particularly in burn injuries and sepsis. Rapid detection of these 
pathogens can monitor these infections in a timely manner improving clinical outcomes. 
Conventional bacterial detection methods, such as agar plate culture or polymerase chain 
reaction, are time-consuming and dependent on complex and expensive instruments, which are 
not suitable for point-of-care (POC) settings. Therefore, there is an unmet need to develop a 
simple, rapid method for detection of pathogens such as Escherichia coli. Here, we present an 
immunobased microchip technology that can rapidly detect and quantify bacterial presence in 
various sources including physiologically relevant buffer solution (phosphate buffered saline 
[PBS]), blood, milk, and spinach. The microchip showed reliable capture of E. coli in PBS with 
an efficiency of 71.8% ± 5% at concentrations ranging from 50 to 4,000 CFUs/mL via lipopoly-
saccharide binding protein. The limits of detection of the microchip for PBS, blood, milk, and 
spinach samples were 50, 50, 50, and 500 CFUs/mL, respectively. The presented technology 
can be broadly applied to other pathogens at the POC, enabling various applications including 
surveillance of food supply and monitoring of bacteriology in patients with burn wounds.
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Introduction
Sepsis is a significant, life-threatening problem for military personnel and civilians 
alike. Clinicians typically make an initial diagnosis of infection with an intermittent 
examination observing changes in temperature, blood pressure, smell, and sight. 
Depending on the severity of the inflicted wound and infectious agent, this may cause 
multiple organ dysfunction, hypoperfusion, failure of body systems (including the 
kidneys, liver, lungs, and central nervous system), and ultimately death. For sepsis 
diagnosis, daily culture and/or molecular analysis is performed using a small volume 
of the patient’s blood; usually less than 0.1% of entire blood volume (ie, approximately 
5 mL). These detection methods are time-consuming and unreliable for identification of 
pathogens in up to 50% of septic patients. Following pathogen detection, the patient is 
treated with broad-spectrum antibiotics; this is not an ideal solution, because frequent use 
of  broad-spectrum antibiotics also stimulates development of antibiotic-resistant bacteria. 
Antibiotic-resistant bacteria are a significant problem for injured military personnel and 
military treatment facilities. Currently, the sepsis mortality rate is 30%–50% among 
civilians and is higher in patients with military conditions including burns, trauma, and 
surgery.1 Although sepsis biomarkers, inflammatory modulators, and new antibiotics 
have been identified in past sepsis research, improved identification of various targets has 
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had minimal impact on sepsis related morbidity and mortality. 
Therefore, there is a significant clinical need for new detection 
and identification technologies in this area. According to 
the Centers for Disease Control and Prevention, food-borne 
diseases cause approximately 76 million illnesses, 325,000 
hospitalizations, and 5,000 deaths in US alone each year.2 
The US Department of Agriculture showed that medical costs, 
productivity losses, and costs of premature deaths caused by 
food-borne diseases are approximately $6.9 billion per year.3 
In 2011, pathogen-based produce contamination triggered 
a global concern with the outbreak of the foodborne toxin 
‘Shiga’, which is produced by Escherichia coli (E. coli).4 
On the other hand, sepsis is the tenth leading cause of death 
in the US,5 amounting to 24,179 cases in 49 US hospitals 
over a period of 7 years.6 As reported, E. coli can contaminate 
food source7 and cause sepsis in burn patients.8,9 Thus, effective 
E. coli detection would have a positive impact.
Currently, the gold standard detection method for bacteria 
is agar plate culture. However, this method is limited by the 
culturing time and volume of sample required to determine 
the presence of pathogens (Figure 1). Due to the challenge 
of obtaining enough sample volume, agar plate cultures give 
false negative results at rates ranging from 7.2% to 21.2%.10,11 
In addition, the process is complicated by the fact that clini-
cal samples need to go through multiple post-cultural steps 
for analysis, including Giemsa staining and differentiation 
on MacConkey plates.12 The whole process takes 48 to 
72 hours.13 Although polymerase chain reaction (PCR) has 
high sensitivity and specificity,14 the need for a thermal cycler 
makes it unsuitable for point-of-care (POC) testing.15 Therein 
lies the niche for which microfluidic technologies are ideal; 
they have been employed to develop POC testing devices 
because of low manufacturing cost, reduced consumption of 
samples and reagents, and shortened assay time.15–20 However, 
existing microfluidic devices for bacterial detection, either 
based on PCR21 or enzyme-linked immunosorbent assay 
(ELISA), require multiple sample   processing steps prior to 
detection.22,23 All of these methods   suffer from   challenges 
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Figure 1 Comparison of the conventional culture method and the microchip based E. coli detection. (A) Conventional procedure for bacteria detection in clinical facilities. 
Blood sample collection. (1) Blood samples are incubated in an automated blood culture system. (2) Pathogen or bacteria grown on agar plate are subject to Gram-staining for 
differentiation between Gram-positive and negative strains. (3) The sample is sub-cultured into a nutrient-rich agar plate for the identification of the species and to determine 
the bacterial concentration. (B) POC testing approach for rapid detection. Blood sample collection (spiked with GFP-expressing E. coli BL21stock as a model microorganism). 
(1) The blood sample is analyzed in microchannels functionalized with E. coli antibodies. E. coli were specifically captured by antibodies on the microchannel surface.   
(2) Unbound E. coli are washed away with PBS using a syringe micropump. (3) GFP-expressing E. coli are imaged/counted under a fluorescence microscope. 
Abbreviations: E. coli, Escherichia coli; GFP, green fluorescent protein; LBP, lipopolysaccharide binding protein; PBS, phosphate buffered saline; POC, point-of-care.
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including culture time, need of high sample volumes and 
reagents, the requirement for preprocessing of samples, low 
accuracy of the pathogen detection, and high cost. Further, for 
the detection of rare bacteria, PCR and ELISA based methods 
require large initial sample volumes, and preprocessing of 
samples, and sample amplification. Thus, there is an unmet 
need to develop POC devices that can address these issues, 
and capture, isolate and detect bacteria from biologically 
complex samples such as blood and produce.
To address this unmet need, we developed a POC 
microchip for capture, isolation, and detection of E. coli 
in various samples such as physiological buffer solution 
(phosphate buffered saline [PBS]), blood, milk, and spinach in 
a simple and rapid manner. This microchip technology could 
be broadly used as a POC device for multiple applications to 
rapidly screen for bacteria contamination in blood and food 
samples, thus improving healthcare and food safety.
Materials and methods
Device fabrication
The microfluidic device was fabricated as previously 
reported.18,24,25 The device was designed with dimensions 
of 22 mm × 60 mm with three parallel microchannels. To 
assemble this device, poly(methyl methacrylate) (PMMA) 
(1.5 mm thick; McMaster Carr, Atlanta, GA) and double-
sided adhesive film (DSA) (50 µm thick; iTapestore, Scotch 
Plains, NJ) were cut using a laser cutter (Versa Laser™, 
Scottsdale, AZ). The PMMA base and a glass cover slip 
were then assembled via the DSA. In the assembled E. coli 
detection device, three microchannels (with dimensions of 
50 mm × 4 mm × 50 µm in the DSA layer) were formed with 
an inlet and outlet (0.565 mm in diameter) at each end of 
the channels in the DSA layer. Before assembling the chip, 
glass cover was cleaned with ethanol using sonication. Then, 
it was washed with distilled water and dried under nitrogen 
gas. After cleaning steps, the glass cover was plasma treated 
for 60 seconds. Then, PMMA, DSA, and glass cover were 
assembled to form the complete microchip (Figure 2A).
Strains used in studies: genetically 
modified E. coli
To validate the surface chemistry, a genetically modified 
E. coli strain expressing emerald green fluorescent protein 
(EmGFP) was used. The E. coli strain BL21 Star™, and 
Poly methyl methacrylate (PMMA)
Double sided adhesive (DSA)
Glass cover slip
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Figure 2 Evaluation of two different surface chemistry methods for E. coli detection on chip. (A) Assembly of the microfluidic chip consisting of PMMA, DSA, and glass 
cover. Actual image of the assembled microchip containing food dye for visualization. (B) Two antibody immobilization mechanisms were employed, ie, Protein G and 
NeutrAvidin based surface chemistry. In the first method, biotinylated anti-LBP antibody was immobilized on the microchannel surface via NeutrAvidin. Then, LBP was 
immobilized on anti-LBP antibody. In the second method, CD14, anti-LPS, or anti-flagellin antibodies was immobilized on the microchannel surface via Protein G. Only 
CD14 immobilization was illustrated and similar steps were followed for anti-flagellin and anti-LPS. (C) Detection of GFP-tagged E. coli on-chip. To validate the E. coli 
capture process, and quantify the on-chip concentration and capture efficiency of E. coli, these cells were identified under brightfield (100× magnification) and fluorescence 
microscopy. (i) Image of the control experiment without E. coli at 10× magnification under a fluorescence microscope. (ii) Image of the capture of GFP-tagged E. coli at 
10× magnification under a fluorescence microscope. (iii) Image of the capture of GFP-tagged E. coli at 100× magnification under a fluorescence microscope. (iv) Image of 
the captured GFP-tagged E. coli at 100× magnification under bright field. 
Abbreviations: DSA, double-sided adhesive film; E. coli, Escherichia coli; GFP, green fluorescent protein; LBP, lipopolysaccharide binding protein; LPS, lipopolysaccharide;   
PBS, phosphate buffered saline; PMMA, poly(methyl methacrylate); POC, point-of-care; GMBS, N-(gamma-maleimidobutyryloxy) succinimide.
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EmGFP-expressing plasmid were purchased from Invitrogen 
(Carlsbad, CA). According to the manufacturer’s instructions, 
the pRSET/EmGFP plasmid, which confers ampicillin 
resistance and green fluorescence, (Invitrogen, catalog 
number V353-20) was transferred into BL21 Star™ by 
incubating at 41°C for 30 seconds and transferring onto ice. 
The transformed BL21 Star™ was then incubated at 37°C 
by shaking at 250 rpm for an hour in Super Optimal broth 
with catabolite repression medium. Following this step, BL21 
Star™ was streaked onto Luria–Bertani (LB) agar plates 
containing 100 mg/mL of ampicillin, and then incubated at 
37°C for 16 hours. An isolated E. coli colony was picked and 
inoculated in 5 mL of LB medium on another LB agar plate, 
with 100 mg/mL of ampicillin added. The E. coli culture 
was then incubated at 37°C with shaking at 250 rpm for 
16 hours. The E. coli culture was then aliquoted, and used 
as a standard stock for all experiments. The E. coli stock 
was diluted ten-fold in PBS and spread on LB-ampicillin 
plates. After overnight incubation at 37°C, single colonies 
of E. coli were counted and the number was used to calculate 
the original concentration of the E. coli stock.
Surface chemistry
Two different surface chemistry methods were evaluated to 
immobilize antibodies for the highest capture efficiency of 
E. coli on chip (Figure 2B). Protein G is an immunoglobulin-
binding protein and has the ability to immobilize the fragment 
crystallization (Fc) region of antibodies. NeutrAvidin has 
strong affinity for biotin-conjugated biomolecules (eg, 
biotinylated antibodies). In the first method, a biotinylated 
antibody was immobilized via NeutrAvidin-based surface 
chemistry.18 Briefly, a glass slide was first plasma treated 
to make the surface more hydrophilic. 200 mM of 
3-mercaptopropyl-trimethoxysilane (100 µL) dissolved in 
ethanol was then injected through the channels and incubated 
for 30 minutes at room temperature. 2 mM of N-(gamma-
maleimidobutyryloxy) succinimide ester (GMBS; 100 µL) 
in ethanol, a cross linker of proteins to antibodies, was 
then incubated in microchannels for 35 minutes at ambient 
temperature. An ethanol wash of 300 µL was performed to 
remove the excess of untreated reagents after each incubation 
step. Before NeutrAvidin binding on the microchannels, 
300 µL of PBS was used to wash out ethanol from the chip 
surface. 30 µL of NeutrAvidin solution (1 mg/mL in PBS) 
was incubated for 1 hour at room temperature before capture 
antibody immobilization. Three different experimental 
designs were performed for the NeutrAvidin studies. In 
the first design, 30 µL of biotinylated lipopolysaccharide 
(LPS) binding protein (LBP) Ab solution (5 µg/mL), (goat 
immunoglobulin G antibody, R&D Systems, Minneapolis, 
MN) was subsequently immobilized on the microchannel 
surface. Then, 30 µL of carrier-free recombinant human LBP 
(R&D Systems) at a concentration of 10 µg/mL was coated 
on the top of biotinylated anti-LBP antibody (anti-LBP-
LBP). In the second design, the same process as performed 
in the first design was followed by the addition of 30 µL 
of bovine serum albumin (BSA) to block any remaining 
reactive spaces on the surface (anti-LBP-LBP-BSA). In the 
third design, first LBP was directly bound to GMBS to test 
the effect of protein orientation on E. coli capture, and then 
the BSA blocking step was performed after LBP binding 
(LBP-BSA). LBP was incubated in microchannels for 1 hour 
at room temperature.
In  the  second  surface  chemistry  method,  three 
nonbiotinylated antibodies (ie, anti-LPS antibody, cluster 
of differentiation 14 protein (CD14) of human monocyte and 
antiflagellin antibody) were immobilized onto microchannels 
via Protein G.26 In this method, processing steps were same 
as the first method except for the use of Protein G instead 
of NeutrAvidin. The Protein G concentration used in the 
immobilization of alternate antibodies onto the surface 
was 1 mg/mL. Then 30 µL of 5 µg/mL anti-LPS antibody 
(Abcam, Cambridge, MA) was immobilized on the surface 
via Protein G. 30 µL of CD14 (Abcam, Cambridge, MA) 
was used at 5 µg/mL to capture E. coli by binding to LPS 
on E. coli surface. Movement of LPS monomers to a binding 
site on CD14 was catalyzed by LBP.27,28 Finally, 30 µL of 
antiflagellin antibody (BioLegend, San Diego, CA) was used 
at a concentration of 5 µg/mL to capture E. coli via the surface 
protein flagellin (part of flagellum).29 These three capture 
agents were simultaneously incubated in microchannels for 
1 hour at room temperature.
Sample preparation
EmGFP-expressing E. coli was spiked into 1 × PBS, blood, 
milk, and spinach samples with the final concentrations 
ranging from 50 to 4,000 colony forming units (CFUs) per 
milliliter for analysis on chip.   Discarded de-identified whole 
blood (purchased from Research Blood Components, LLC, 
Cambridge, MA) was used in this study. Whole blood was 
spiked with E. coli and then inverted gently for 1 hour to 
enable homogenous distribution of E. coli. Spinach and 
milk samples were obtained from a local grocery store. 
Spinach leaves were washed and then spiked with E. coli 
before thorough mixing in a blender with 100 mL of sterile 
deionized H2O. The resultant mixture containing E. coli was 
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filtered through a cell strainer (70 µM) to remove the residues   
of spinach leaves prior to microchip testing. Milk was spiked 
with E. coli and vortexed for 1 minute before testing.
Device operation and on-chip detection
To optimize the capture efficiency, 75 µL of EmGFP-
  expressing E. coli sample was pipetted into the functionalized 
microchannels, and then incubated at ambient temperature 
for 30 minutes. Following the incubation, microchannels 
were washed with 300 µL of PBS at a flow rate of 
2 µL/minute using a syringe pump (Harvard Apparatus, 
Holliston, MA) for 150 minutes. For further optimization of 
processing time 2, 5, and 10 µL/minute wash was performed. 
After washing,   captured E. coli was imaged using an inverted 
fluorescence microscope (Carl Zeiss, Thornwood, NY) 
through a GFP fluorescence filter (excitation wavelength 
470 nm). For comparison, bright field and fluorescence 
images of E. coli taken under 10× and 100× magnification 
were merged (Figure 2C). The number of E. coli detected 
under 10× magnification using a GFP filter was counted 
manually.
Statistical analysis
To evaluate the effect of the capture agent on capture 
efficiency, we analyzed the experimental results (n = 2–6) 
using analysis of variance with Tukey’s post-hoc test for 
multiple comparisons with statistical significance threshold 
set at 0.05 (P , 0.05). To evaluate the effect of flow rate 
on capture efficiency, we analyzed the experimental results 
(n = 3–8) using nonparametric Kruskal–Wallis test followed 
by pair-wise comparisons with nonparametric upper-tailed 
Mann–Whitney U test, with statistical significance threshold 
set at 0.05 (P , 0.05). When nonparametric pair-wise 
tests were performed, Bonferroni correction was used for 
multiple comparisons. The agreement between chip counts 
and the E. coli stock concentrations in different media 
(PBS, blood, milk, spinach) was evaluated by calculating 
Pearson product-moment correlation coefficient (r) with 
statistical significance threshold set at 0.05 (P , 0.05). The 
Bland–Altman comparison analysis was used to evaluate the 
repeatability of the chip counts using residual analysis in 
comparison to E. coli stock concentrations. The coefficient 
of repeatability was calculated as 1.96 times the standard 
deviations of the differences between chip measurements 
and E. coli stock concentrations. In the Bland–Altman 
analysis, a mean difference of zero indicates that the chip 
measurement is unbiased with respect to the standard. 
A clinically acceptable range indicates the interval within 
which the difference would fall approximately 95% of 
the time. If the mean difference and the limit of agreement 
are within the clinically acceptable range, then the developed 
measurement method is deemed comparable to the standard. 
Statistical analyses were performed with Minitab (Release 
14; Minitab Inc, State College, PA).
Results and discussion
We engineered the surface chemistry using immobilized 
antibodies, where the performance of the chip relies on 
nanoscale reactions on the microchannel surface. We evaluated 
antibodies specific to E. coli surface proteins using commonly 
reported antibody immobilization methods that provide a 
uniform distribution of antibodies on the capture surface in 
microfluidic channels, ie, Protein G and NeutrAvidin based 
methods. To develop a rapid microchip method for E. coli 
detection, four different capturing agents were immobilized 
in microchannels via these two surface chemistry methods. 
As shown in Figure 2B, anti-LPS, antiflagellin, and CD14 
were immobilized on the microchannel surface via Protein G 
and anti-LBP antibody was immobilized on the microchannel 
surface via NeutrAvidin. To investigate the binding of 
anti-LBP antibody, and to observe the effect of antibody 
orientation on E. coli capture. Three different experimental 
designs were performed. In NeutrAvidin experiments, capture 
efficiencies of anti-LBP-LBP, anti-LBP-LBP-BSA, and LBP-
BSA were observed to be 71.8% ± 5%, 60.7% ± 2%, and 
44.5% ± 5%, respectively (Figure 3A). In comparison, E. 
coli capture efficiencies of antiflagellin, anti-LPS and CD14 
obtained by using Protein G based surface chemistry, were 
46.9% ± 3%, 41.5% ± 5%, and 41.0% ± 2%, respectively 
(Figure 3A). The capture efficiency via anti-LBP-LBP 
was observed to be significantly greater (P , 0.05) than 
the other capture agents that were used with Protein G 
based surface chemistry (Figure 3A). In our prior study, 
Protein G and NeutrAvidin exhibited similar efficiency 
to immobilize capture agents on microchannel surfaces.26 
Thus, the difference in capture efficiency of E. coli was 
mainly due to the affinity of capture agents, ie, anti-LPS, 
antiflagellin, CD14, and LBP. The highest capture efficiency 
(71.8% ± 5%) was observed in microchannels immobilized 
with anti-LBP in the presence of LBP. This observation is in 
accordance with a previous report, in which LBP was shown 
to bind E. coli with high affinity; anti-LBP antibody helped 
the protein to take favorable orientation for E. coli capture.27 
BSA blocking was used to prevent nonspecific binding 
in microchannels in addition to preventing the binding of 
anti-LBP antibodies and LBP onto the succinimide group 
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of GMBS. The use of BSA as a blocking agent did not result in 
a  statistically significant difference in capture efficiency with 
both anti-LBP-LBP and anti-LBP-LBP-BSA. The LBP-BSA 
experiment showed that the orientation of the LBP protein is 
critical to capture of E. coli, which was supported by statistical 
analysis of experimental results as shown in Figure 3A. As an 
overall result, Neutr  Avidin-mediated anti-LBP antibody-LBP 
immobilization performed on the microchannel surface to 
attain high capture efficiency of E. coli.
By investigating the effects of washing flow rate on 
E. coli capture efficiency, anti-LBP antibody based surface 
chemistry was further optimized. At the flow rates of 2, 
5, and 10 µL/min, capture efficiencies were 70.7% ± 4%, 
60.5% ± 3%, and 53.9% ± 8%, respectively (Figure 3B). 
Statistical analysis on experimental results indicated that 
flow rate had a significant effect on capture efficiency 
(nonparametric Kruskal–Wallis test), where 2 µL/min 
resulted in significantly greater (P , 0.05) capture efficiency 
compared to 10 µL/min. The lower efficiency observed at 
higher flow rates may be related to the correspondingly 
higher shear stress within the microchannels. Additionally, 
we used food dyes to visualize and qualitatively analyze the 
wash steps in microchannels. We observed that the selected 
flow rate (2 µL/min) achieved effective removal of food dye 
solution from microchannels (Figure 4).
To determine the microchip’s limit of detection for E. coli 
capture, we used LB agar plate culture as the gold standard 
for E. coli detection. We correlated agar plate results for a 
Figure 4 (A) Three different food dye solutions were injected into microchannels before performing wash steps. (B) Images of channels before and after wash steps indicated 
that food dye was removed from microchannels at a flow rate of 2 µL/minute.
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Figure 3 Comparison of the capture efficiency of E. coli by two different surface chemistries and different capturing agents. E. coli were incubated at room temperature for 
1 hour. (A) Three different experimental designs (anti-LBP-LBP, anti-LBP-LBP-BSA, and LBP-BSA) were performed on NeutrAvidin based surface chemistry. Three different 
capture agents were immobilized via Protein G based surface chemistry. The wash flow rate was 2 µL/min. Brackets connecting individual groups indicate statistically significant 
difference (analysis of Variance with Tukey’s post-hoc test for multiple comparisons, n = 2–6, P , 0.05). (B) Effect of channel flow rate on capture efficiency of E. coli on chip. 
75 µL of E. coli was flowed into microchannels. After sample incubation for 15 min at ambient temperature, three different wash flow rates (2, 5, and 10 µL/min) were used to 
optimize the capture efficiency of E. coli on chip. Statistical analysis indicated that flow rate had a significant effect on capture efficiency (nonparametric Kruskal–Wallis test), 
where 2 µL/min resulted in significantly greater (P , 0.05) capture efficiency compared to 10 µL/min flow rate. Brackets connecting individual groups indicate statistically 
significant difference. Data are presented as average ± SEM. Non-parametric upper-tailed Mann–Whitney U test for pair-wise comparisons, n = 3–8, P , 0.05. 
Abbreviations: BSA, bovine serum albumin; E. coli, Escherichia coli; LBP, lipopolysaccharide binding protein; SEM, standard error of the mean. 
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Figure  5  Correlation  of  E.  coli  quantification  by  microchip  and  LB  plating.  This  experiment  was  performed  to  establish  the  correlation  between  bacteria  cell 
counts  obtained  by  colony  count  from  LB  agar  plates  and  cell  count  after  capture  on  a  microfluidic  device  (A, C , E   and  G).  Bland–Altman  analysis  between 
the  microchip  count  and  E.  coli  stock  concentrations  did  not  display  an  evidence  for  a  systematic  bias  for  chip  counts.  (A)  75  µL  of  varying  concentrations 
(up to 500 CFUs/mL) of E. coli spiked in PBS was injected into microchannels functionalized with anti-LBP antibody. For comparison, 75 µL of each concentration 
of E. coli was plated out on ampicillin containing LB agar plates and incubated overnight. The number of E. coli colonies was counted the next day and compared to 
the  E.  coli  counted  on  chip.  The  detection  limit  of  microchip  was  found  as  50  CFUs/mL.  Data  are  presented  as  average  ±  SEM  (n  =  3)  (r  =  0.960,  P  =  0.009).   
(B) The mean bias for E. coli spiked in PBS was −70 CFUs/mL sample in microchip counts compared to E. coli stock concentrations. (C) Varying concentrations (up to 
400 CFUs/mL) of E. coli spiked in blood were injected into microchannels functionalized with anti-LBP antibody and the detection limit of microchip was found as 50 CFUs/mL 
(r = 0.989, P = 0.011). (D) The mean bias was −165 CFUs/mL of blood in microchip counts compared to E. coli stock concentrations. (E) Varying concentrations (up to 
400 CFUs/mL) of E. coli spiked in milk were injected into microchannels functionalized with anti-LBP antibody and the detection limit of microchip was found as 50 CFUs/mL   
(r = 0.962, P = 0.038). (F) The mean bias was −163 CFUs/mL of milk in microchip counts compared to E. coli stock concentrations. (G) Varying concentrations (up to 4,000 
CFUs/mL) of E. coli spiked in spinach were injected into microchannels functionalized with anti-LBP antibody and the detection limit of microchip was found as 500 CFUs/mL   
(r = 0.977, P = 0.023). (H) The mean bias was −1869 CFUs/mL of spinach sample in microchip counts compared to E. coli stock concentrations. (“r” indicates Pearson product-
moment correlation coefficient, “P” indicates the statistical significance of correlation).
Abbreviations: CFU, colony forming unit; E. coli, Escherichia coli; LB, Luria–Bertani; LBP, lipopolysaccharide binding protein; SD, standard deviation; SEM, standard error of 
the mean.
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series of known concentrations of E. coli with the microchip 
capture results. E. coli concentration and microchip-based 
E. coli detection showed a positive correlation for E. 
coli concentrations ranging from 50 to 4,000 CFUs/mL 
(Figure 5). The linearity of the correlation indicates that 
microchip-based E. coli detection can be used as an alterna-
tive to agar plate culture.
Figure 5A shows a sensitivity of 50 CFUs/mL that was 
obtained by the microchip count in PBS. Various sample 
types including blood, milk, and spinach, were used for 
rapid on-chip detection of E. coli (Figure 5C, E, and G). 
The detection limits of E. coli in blood, milk, and spinach 
samples were observed to be 50, 50, and 500 CFUs/mL as 
compared to E. coli dilution count, respectively. According 
to Bland–Altman analysis, the mean biases were –70 CFUs/
mL, –165 CFUs/mL, –163 CFUs/mL, and –1869 CFUs/
mL for PBS (50 to 500 CFUs/mL), blood (50 to 500 CFUs/
mL), milk (50 to 500 CFUs/mL), and spinach (500 to 4,000 
CFUs/mL) samples, respectively (Figure 5B, D, F, and H). 
Compared to E. coli spiked in PBS, the capture efficiency 
and limit of detection slightly decreased in other samples 
due to the immunological and enzymatic components in 
blood, milk, and spinach. For instance, there is a significant 
amount of albumin present in blood; this is commonly 
used as a blocking agent in immunoassays, and as such 
may have had a similar effect on our experiment. Milk also 
tends to have excessive albumin, casein, and other proteins, 
which may cause further blocking of the antigen-antibody 
binding. As the data show, these blocking and enzymatic 
agents can affect the capture efficiency. E. coli detection in 
spinach samples showed higher limit-of-detection than milk 
and blood experiments, potentially due to this experiment 
requiring preprocessing steps to remove the residuals of 
spinach leaves prior to microchip testing. Preprocessing 
steps (eg, filtering) caused a loss in E. coli cells before 
detection. On the other hand, the presented microchip assay 
achieved a lower detection limit for similar assays than was 
previously reported by methods such as magnetic separation 
method, fluorescence staining, and electrical detection 
(104 CFUs/mL and 8 × 104 CFUs/mL, respectively).30,31 Since 
nucleic acid-based-detection methods require more extensive 
sample preprocessing, antibody based E. coli detection 
on a chip presents a simpler alternative method to nucleic 
acid-based amplification assays on a chip.32,33 The current 
culture-based systems are subject to giving false negatives 
since only a small sample can be cultured compared to the 
whole sample volume, eg, 0.1% of the total blood volume 
is cultured in sepsis patients. This leads to 7.2 to 21.2% 
of such cultures providing false negatives.10,11 With the 
microchip system, larger sample sizes can be processed by 
continuous flow, giving results much faster than a culture 
system. The sample can also be reprocessed within either 
the same or new microchannels; this would be expected to 
increase the number of pathogens captured from a single 
sample. However, for detection purposes, this would be not 
necessary granted that accurate detection results are provided 
by the chip. Capturing larger numbers of pathogens can 
be beneficial for other applications such as culturing and 
downstream genomic analysis.
In this study, we used E. coli as a model pathogen 
because E. coli have been extensively characterized, 
and as such it provides simple comparison to existing 
systems. We transformed BL21 Star™ with EmGFP-
expressing plasmid and developed a microfluidic device 
to rapidly capture and quantify E. coli from various 
biological samples. The GFP-expressing E. coli was used 
to facilitate the quantification steps. The bacteria can be 
visualized either under a microscope in a laboratory setting, 
or for rapid counts in POC settings, with wide field of 
view lensless imaging systems for rapid counts for POC 
settings.20,24,25,34 Also, for characterization of E. coli capture 
from various biological samples, we employed a GFP-
expressing strain for ease of detection under a fluorescence 
microscope. The extension from a GFP-expressing strain 
to wild-type strains can be simply achieved using an 
ELISA-based detection method, as previously reported.35 
The characterized microchip can be coupled with 
POC detection technologies such as surface plasmon 
resonance,36–38 on-chip ELISA,39 and lensless imaging20,24 
to achieve POC testing without reference to laboratory 
equipment. Additionally, the presented microfluidic 
approach can be adapted to detect other microorganisms 
that cause sepsis such as Gram-negative bacteria (E. coli, 
Klebsiella, Pseudomonas, Enterobacter, and Hemophilus 
species) and Gram-positive bacteria (Staphylococcus, 
Streptococcus, and Enterococcus species).40 Also, the 
current material cost, without the labor and other costs of 
the microchip, includes 10¢ of glass, 1¢ of PMMA, and 
70¢ of antibodies. The antibody cost could be lowered with 
large-scale production and ordering.
In conclusion, we presented a microfluidic immunoassay 
to capture E. coli from blood, milk and spinach samples. 
This microchip enables rapid detection of bacteria in blood 
samples and food supply. The technology can be potentially 
adapted for on-site real-time food quality monitoring and 
for diagnosis of sepsis at the POC.
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